Chronic Rhinosinusitis with Nasal Polyps - Pipeline Insight, 2022

Chronic Rhinosinusitis with Nasal Polyps - Pipeline Insight, 2022

DelveInsight’s, “Chronic Rhinosinusitis with Nasal Polyps - Pipeline Insight, 2022,” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Chronic Rhinosinusitis with Nasal Polyps pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

Global coverage

Chronic Rhinosinusitis with Nasal Polyps Understanding

Chronic Rhinosinusitis with Nasal Polyps: Overview

Chronic rhinosinusitis with nasal polyps (CRSwNP) is a condition that can cause frustrating symptoms, from sinus pain and nose stuffiness to loss of smell. Nasal polyps are growths in the nose or sinuses. They are not cancerous, but they can make you miserable and interfere with your quality of life and make sleeping difficult. Treatment includes nasal or oral medications, biologic injections, and surgery. However, these polyps may grow back. Symptoms include anterior or posterior rhinorrhea, nasal congestion, hyposmia and/or facial pressure or pain that last for greater than 12 weeks duration. Nasal polyps are inflammatory lesions that project into the nasal airway, are typically bilateral, and originate from the ethmoid sinus. Males are more likely to be affected than females but no specific genetic or environmental factors have been strongly linked to the development of this disorder to date. CRSwNP is frequently associated with asthma and allergic rhinitis but the cellular and molecular mechanisms that contribute to the clinical symptoms are not fully understood. Defects in the sinonasal epithelial cell barrier, increased exposure to pathogenic and colonized bacteria, and dysregulation of the host immune system are all thought to play prominent roles in disease pathogenesis. Medical treatment options for patients with CRSwNP remain limited. According to the most recent US guidelines, both topical corticosteroids and nasal saline irrigations are recommended as initial medical therapies for affected patients

""Chronic Rhinosinusitis with Nasal Polyps - Pipeline Insight, 2022"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Chronic Rhinosinusitis with Nasal Polyps pipeline landscape is provided which includes the disease overview and Chronic Rhinosinusitis with Nasal Polyps treatment guidelines. The assessment part of the report embraces, in depth Chronic Rhinosinusitis with Nasal Polyps commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Chronic Rhinosinusitis with Nasal Polyps collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

A better understanding of disease pathogenesis contributing to the development of novel therapeutics for Chronic Rhinosinusitis with Nasal Polyps.

In the coming years, the Chronic Rhinosinusitis with Nasal Polyps market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.

The companies and academics that are working to assess challenges and seek opportunities that could influence Chronic Rhinosinusitis with Nasal Polyps R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.

A detailed portfolio of major pharma players who are involved in fueling the Chronic Rhinosinusitis with Nasal Polyps treatment market. Several potential therapies for Chronic Rhinosinusitis with Nasal Polyps are under investigation. With the expected launch of these emerging therapies, it is expected that there will be a significant impact on the Chronic Rhinosinusitis with Nasal Polyps market size in the coming years.

Our in-depth analysis of the pipeline assets (in early-stage, mid-stage and late stage of development for the treatment of Chronic Rhinosinusitis with Nasal Polyps) includes therapeutic assessment and comparative analysis. This will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.

Chronic Rhinosinusitis with Nasal Polyps Emerging Drugs Chapters

This segment of the Chronic Rhinosinusitis with Nasal Polyps report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Chronic Rhinosinusitis with Nasal Polyps Emerging Drugs

CM310: Keymed Biosciences

CM310 recombinant humanized monoclonal antibody injection is an innovative humanized monoclonal antibody self-developed by Keymed Bioscience (Chengdu) Co., Ltd., the first in China targeting human IL-4 receptor alpha subunit (IL-4Rα) and completed Phase II clinical trial. CM310 can selectively combine with IL-4Rα to block out the combination of IL-4Rα and IL-4 as well as IL-13, thus suppressing its bioactivity. Currently, it is in Phase II stage of clinical trial evaluation to treat chronic sinusitis with nasal polyps.

CBP 201: Connect Biopharma

CBP-201 is a human monoclonal antibody targeting IL-4Rα, which we have observed to have dose-dependent and differentiated pharmacokinetics and pharmacodynamics in an early clinical trial. As an inhibitor of IL-4Rα, CBP-201 blocks inflammatory signaling by both IL-4 and IL-13. CBP-201 binds to a region of IL-4Rα that is distinct from that bound by dupilumab (an antibody that targets IL-4Rα and is marketed as Dupixent®). The clinical development program is focused on differentiating CBP-201 in three areas, with the potential to show rapid onset and sustained improvements in clinical outcomes with a convenient dosing frequency.

Further product details are provided in the report……..

Chronic Rhinosinusitis with Nasal Polyps: Therapeutic Assessment

This segment of the report provides insights about the different Chronic Rhinosinusitis with Nasal Polyps drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Chronic Rhinosinusitis with Nasal Polyps

There are approx. 10+ key companies which are developing the therapies for Chronic Rhinosinusitis with Nasal Polyps. The companies which have their Chronic Rhinosinusitis with Nasal Polyps drug candidates in the most advanced stage, i.e. phase II include, Keymed Biosciences.

Phases

DelveInsight’s report covers around 10+ products under different phases of clinical development like

Late stage products (Phase III)

Mid-stage products (Phase II)

Early-stage product (Phase I) along with the details of

Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates

Route of Administration

Chronic Rhinosinusitis with Nasal Polyps pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Inhalation

Inhalation/Intravenous/Oral

Intranasal

Intravenous

Intravenous/ Subcutaneous

NA

Oral

Oral/intranasal/subcutaneous

Parenteral

Subcutaneous

Molecule Type

Products have been categorized under various Molecule types such as

Antibody

Antisense oligonucleotides

Immunotherapy

Monoclonal antibody

Peptides

Protein

Recombinant protein

Small molecule

Stem Cell

Vaccine

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Chronic Rhinosinusitis with Nasal Polyps: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Chronic Rhinosinusitis with Nasal Polyps therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Chronic Rhinosinusitis with Nasal Polyps drugs.

Chronic Rhinosinusitis with Nasal Polyps Report Insights

Chronic Rhinosinusitis with Nasal Polyps Pipeline Analysis

Therapeutic Assessment

Unmet Needs

Impact of Drugs

Chronic Rhinosinusitis with Nasal Polyps Report Assessment

Pipeline Product Profiles

Therapeutic Assessment

Pipeline Assessment

Inactive drugs assessment

Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

How many companies are developing Chronic Rhinosinusitis with Nasal Polyps drugs?

How many Chronic Rhinosinusitis with Nasal Polyps drugs are developed by each company?

How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Chronic Rhinosinusitis with Nasal Polyps?

What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Chronic Rhinosinusitis with Nasal Polyps therapeutics?

What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

What are the clinical studies going on for Chronic Rhinosinusitis with Nasal Polyps and their status?

What are the key designations that have been granted to the emerging drugs?

Key Players

Keymed Biosciences

Connect Biopharma

AstraZeneca

Amgen

Pfizer

Trellis Bioscience LLC

GlaxoSmithKline

Gossamer Bio Inc.

Biohaven Pharmaceuticals, Inc.

Insmed Incorporated

Lyra Therapeutics

Key Products

CM310

CBP-201

CM326

Tezepelumab

PF-06817024

TRL1068

Depemokimab

Benralizumab

GB001

Rimegepant

LYR-210